# Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

> **NCT02314156** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 67 (actual)

## Conditions studied

- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Ductal Breast Carcinoma In Situ
- Lobular Breast Carcinoma In Situ
- Stage 0 Breast Cancer
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer

## Interventions

- **DRUG:** Telapristone Acetate
- **OTHER:** Placebo
- **DRUG:** Telapristone Acetate
- **OTHER:** Placebo
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02314156
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-01
- **Final completion:** 2021-05
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314156, "Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02314156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*